NCI-H23細(xì)胞

細(xì)胞形態(tài)： 上皮樣

是否是腫瘤細(xì)胞： 1

物種來(lái)源： 人

器官來(lái)源： 肺

生長(zhǎng)狀態(tài)： 貼壁生長(zhǎng)

ATCC Number： CRL-5800?

數(shù)量： 大量

相關(guān)**： 非小細(xì)胞肺癌

運(yùn)輸方式： 凍存運(yùn)輸

年限： 51 years

Designations: NCI-H23 [H23]

NCI-H23細(xì)胞Depositors: AF Gazdar, JD Minna

Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: adherent

Organism: Homo sapiens

Morphology: epithelial

Source: Organ: lung

Disease: adenocarcinoma; non-small cell lung cancer

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Restrictions: NCI-H23細(xì)胞The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.

Oncogene: myc +; src +; abl +; erb +; ras +; sis -

DNA Profile (STR): Amelogenin: X

CSF1PO: 10

D13S317: 12

D16S539: 11

D5S818: 12,13

D7S820: 9,10

THO1: 6

TPOX: 8,9

vWA: 16,17

Age: 51 years

Gender: male

Ethnicity: Black

Comments: NCI-H23細(xì)胞This line was derived from a lung cancer obtained from a patient prior to therapy.

The cells carry the K-ras 12 mutation, and there is a mutation in codon 246 (ATC -> ATG, isoleucine -> methionine) of the p53 gene.

There is expression of C-myc, L-myc, v-src, v-abl, v-erb B, c-raf 1, Ha-ras, Ki-ras and N-ras RNAs.

The cells express heterogeneous mRNA expression for PDGF A and B chain, transforming growth factor alpha and beta and the epidermal growth factor receptor (EGFR).

NCI-H23 exhibits a high degree of c-myc DNA amplification (20-fold) but no detectable amplification of c-myc RNA.

The cells stain positive for keratins 5+8 and 18 and vimentin but are negative for neurofilament.

NCI-H23 cells are L-dopa decarboxylase-negative.

They have a reported colony forming efficiency of 9.7% in soft agarose.

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Temperature: 37.0°C

Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended

Medium Renewal: Every 2 to 3 days

Remove spent medium, and add fresh 0.25% trypsin, 0.03% EDTA solution for 2 to 3 minutes at room temperature.

Remove the trypsin and incubate the flask at 37C for 5 to 10 minutes or until the cells detach.

Add fresh medium, aspirate and dispense into new flasks.

Preservation: NCI-H23細(xì)胞Culture medium, 95%; DMSO, 5%

Doubling Time: 38 hrs

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001

recommended serum:ATCC 30-2020

References: 1805: Little CD, et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196, 1983. PubMed: 6646201

1806: Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494

22403: Mitsudomi T, et al. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7: 171-180, 1992. PubMed: 1311061

22434: Brower M, et al. Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res. 46: 798-806, 1986. PubMed: 3940644

22465: Broers JL, et al. Spontaneous changes in intermediate filament protein expression patterns in lung cancer cell lines. J. Cell Sci. 91: 91-108, 1988. PubMed: 2473086

22868: Forsberg K, et al. Expression of functional PDGF beta receptors in a human large-cell lung- carcinoma cell line. Int. J. Cancer 53: 556-560, 1993. PubMed: 8382192

23036: Gazdar AF, et al. NCI-H23細(xì)胞Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res. 40: 3502-3507, 1980. PubMed: 6108156

23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996..

24389: . . Lung Cancer 4: 155-161, 1988.